Cooley LLP announced today that it advised the underwriters on Five Prime Therapeutics, Inc.’s initial public offering. Five Prime is a San Francisco-based clinical-stage biotechnology company focused on discovering and developing novel protein therapeutics for cancers and inflammatory diseases. Five Prime now trades on the NASDAQ Global Market under the symbol “FPRX.”

Jefferies LLC, BMO Capital Markets and Wells Fargo Securities, LLC, are acting as joint-book-running managers and Guggenheim Securities, LLC is acting as co-manager for the offering.

The Cooley corporate securities team advising the underwriters was led by partners Dave Peinsipp, Charlie Kim and Drew Williamson, and included associates Veer Bhavnagri, Kristin VanderPas, Carolyn Mo, Amanda Busch and Rebecca Jones. Critical support for the offering was provided by partners Natasha Leskovsek and Drew Gantt and associate David Sclar (regulatory);  partner Bill Christensen and associate Mark Rogel (intellectual property); partner Renee Deming (compensation and benefits) and partner Susan Philpot (tax).

View Five Prime’s press release here.


Related Posts:

Leave a Reply